Dr. Ross has over 30 years experience in the Generics Industry, the last 15 being at corporate level. He has been intimately involved in strategic planning, pipeline management and related activities. His early industrial experience with Teva and Taro were directed primarily to the US markets but later as President of IPR, a company jointly owned by PAR and Merck Generics followed by R&D director for Polpharma, his role expanded to include development for the European markets. Technically Malcolm specializes in development, both of formulations and analytical methodologies and holds a number of patents for novel formulations. He has set up R&D departments from scratch and has been responsible for upgrading existing units to European standards. Experienced in GMP and QA issues Malcolm has carried out many audits worldwide, both for API and Finished dosage forms. In 2006 Malcolm moved to Basel and established Generapharm, a training and consultancy company.